Work

KEYNOTE-365 cohort I: Phase 1b/2 study of pembrolizumab combined with platinum-containing chemotherapy and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.6_suppl.tps218

Authors: Johann S. De Bono, Anthony M. Joshua, Neal D. Shore, Gero Kramer, Xin Tong Li, Christian Heinrich Poehlein, Charles Schloss, Evan Y. Yu

Institutions: Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, St Vincent's Hospital Sydney, Carolina Urologic Research Center, Medical University of Vienna, Merck & Co., Inc., Rahway, NJ, USA (United States), University of Washington

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4213071640

Cites:

Cited by: 3

Related to: 10